News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nvidia fundamentals remain strong but momentum is compressed and short interest is elevated ahead of 11/17 earnings.
  • Tactical bearish trade recommends inverse product NVDL: entry $205.29, target $180, stop $225, 10-day horizon.
  • Alvotech trades at $4.48 and is priced like a company with a broken-factory narrative.
  • Recent approvals and financing materially boost Alvotech's manufacturing capacity and liquidity.
  • Proposed mid-term long uses a 45-trading-day horizon ahead of Q3 results.

Latest Articles

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics announced new formulary agreements that increase access to ZELSUVMI (berdazimer) topical gel, a novel treatment for molluscum contagiosum, to a total of 127 million commercially covered lives plus strong Medicaid coverage. This includes a major Pharmacy Benefit Manager covering 24 million lives without prior authorization and a…

SailPoint Report Finds 79% of Enterprises Run AI Agents in Production, Yet Only 2% Have Deployed Purpose-built Security

SailPoint Report Finds 79% of Enterprises Run AI Agents in Production, Yet Only 2% Have Deployed Purpose-built Security

SailPoint's 2026 Horizons of Identity Security report reveals that while 79% of enterprises have deployed AI agents in production, only 2% have purpose-built identity security controls for them, exposing significant operational and compliance risks. The report emphasizes the urgent need to advance from foundational identity security practices to au…

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

ArriVent BioPharma announced that its Phase 3 FURVENT clinical trial evaluating firmonertinib monotherapy in first-line treatment of locally advanced or metastatic non-squamous NSCLC patients with EGFR exon 20 insertion mutations did not meet its primary endpoint of progression-free survival by blinded independent central review. Although secondary…

Veea Secures Landmark Smart Community Agreement with La Estadia Community for Agentic Real-time Aware and Secure Community

Veea Secures Landmark Smart Community Agreement with La Estadia Community for Agentic Real-time Aware and Secure Community

Veea Inc. has secured a landmark one-year agreement with La Estadia Community to deploy its SecureConnect platform and Veea Vision AI video analytics across 220 residential properties. The project aims to enhance connectivity, cybersecurity, and resident safety through AI-driven edge computing, marking the first phase of broader expansion opportuni…

authID Announces $2 Million Agreement with the EinStrong Foundation

authID Announces $2 Million Agreement with the EinStrong Foundation

authID announced a $2 million technology licensing and service agreement with the EinStrong Foundation, supporting EinStrong's mission to fight poverty and educational inequality worldwide by using authID's biometric identity verification. EinStrong paid $1 million upfront for technology licensing and committed an additional $1 million for biometri…

Mercury Introduces RES One, a Rugged Edge Server Engineered for Rapid Deployment and Superior Lifecycle Management

Mercury Introduces RES One, a Rugged Edge Server Engineered for Rapid Deployment and Superior Lifecycle Management

Mercury Systems introduced RES One, a next-generation rugged edge server designed for rapid deployment, modular upgrades, and reduced sustainment costs in harsh environments. The platform supports long life cycles needed for military and industrial applications by allowing technology refreshes without complete redesigns, and features advanced secur…

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026

Odyssey Therapeutics announced that additional results from the induction period of its Phase 2a trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate to severe ulcerative colitis, will be presented orally at the upcoming UEG Week 2026. The company will also host a conference call to discuss these new data, underscoring progress in thei…

Genius Group Recommences Bitcoin Treasury Purchases

Genius Group Recommences Bitcoin Treasury Purchases

Genius Group Limited (NYSE American: GNS) has recommenced its Bitcoin treasury purchases, acquiring 10 Bitcoin for approximately $854,000, marking progress in its $1.2 billion dual treasury capital plan targeting significant investments in Bitcoin and AI assets by FY2031. This move follows a favorable court ruling lifting restrictions on the compan…

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Telomir Pharmaceuticals secured $5.6 million through a private investment in public equity, including a $1.0 million additional investment from billionaire John Paul DeJoria. The funds will support the clinical development of Telomir-Zn, an oral small-molecule epigenetic therapy entering Phase 1/2 trials for advanced triple-negative breast cancer a…

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

PDS Biotechnology Corporation announced a virtual key opinion leader event featuring Dr. Jonathan M. Hernandez to discuss clinical outcomes from the PDS0301 Phase 2 trials targeting advanced liver-associated metastatic colorectal cancer, focusing on patients with immunotherapy-resistant microsatellite stable tumors. PDS0301 is an investigational IL…

Upexi to Participate in Upcoming October Investor Conferences

Upexi to Participate in Upcoming October Investor Conferences

Upexi, Inc., a NASDAQ-listed digital asset treasury company focused on accumulating Solana cryptocurrency and developing consumer brands, announced its Chief Strategy Officer Brian Rudick will participate in multiple investor conferences in October 2026. The company aims to showcase its strategic initiatives in Solana asset acquisition and consumer…

Tri Pointe Homes Named to Best Workplaces in Construction List by Great Place To Work and Fortune for the Fifth Consecutive Year

Tri Pointe Homes Named to Best Workplaces in Construction List by Great Place To Work and Fortune for the Fifth Consecutive Year

Tri Pointe Homes has been named one of the Best Workplaces in Construction for the fifth year in a row by Great Place To Work and Fortune. This accolade reflects the company's strong culture, commitment to employee development, and inclusive work environment, reinforcing its leadership position in the U.S. homebuilding industry across 13 states and…

Stryker announces leadership succession

Stryker announces leadership succession

Stryker Corporation announces a planned leadership transition effective January 1, 2027, with current CEO Kevin Lobo moving to Executive Chair of the Board and current President and COO Spencer Stiles becoming the new CEO. The transition follows a comprehensive succession planning process and aims to continue Stryker's growth and innovation as a gl…

BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder

BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder

BullFrog AI disclosed progress in its commercial drug discovery program targeting major depressive disorder for a top 5 global pharmaceutical company. Utilizing its proprietary AI platform, the company successfully identified and prioritized novel neuropsychiatric therapeutic targets, validating its technology and reinforcing its commercial strateg…